Frankfurt - Delayed Quote EUR

Viking Therapeutics, Inc. (1VT.F)

23.63

+0.03

+(0.15%)

As of 8:07:31 AM GMT+2. Market Open.

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

Viking Therapeutics has a promising pipeline candidate in the fast-growing therapeutic area of weight loss. Madrigal Pharmaceuticals markets the only approved therapy for a disease whose prevalence is growing. Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns.

Motley Fool 2 days ago

VKTX

MDGL
3 Monster Stocks in the Making

Axsome Therapeutics is taking off, led by a treatment for major depressive disorder. Iovance Biotherapeutics could transform how solid tumors are treated. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance Biotherapeutics (NASDAQ: IOVA), and Viking Therapeutics (NASDAQ: VKTX) are monster stocks in the making.

Motley Fool 4 days ago

VKTX

IOVA

AXSM
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April

Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a relatively young, clinical-stage company, Viking has developed quite a high profile. The company announced formally that it had discontinued the development of its homegrown weight-loss medication danuglipron, following a liver injury to a patient during a clinical trial.

Motley Fool 10 days ago

VKTX

PFE
Why Viking Therapeutics Stock Was Victorious This Week

Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its price rose by almost 18%, according to data compiled by S&P Global Market Intelligence.

Motley Fool 13 days ago

VKTX
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025

Viking Therapeutics (NasdaqCM:VKTX) has experienced a share price increase of 20% over the last month. This comes amidst the company's report of increased financial losses, with a net loss of $46 million in Q1 2025, up from $27 million the previous year, and a change in their auditing firm from Marcum to CBIZ. While these company-specific events likely added some pressure, broader market trends including a significant S&P 500 rally, driven by optimistic earnings reports and potential easing...

Simply Wall St. 13 days ago

VKTX
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

Motley Fool 13 days ago

LLY

NVO

VKTX
Is Novo Nordisk Stock a Buy?

The market for weight loss drugs is white-hot, and competition is heating up fast. This Danish company is already facing a powerful rival in this growing segment. For years, Denmark-based Novo Nordisk (NYSE: NVO) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors.

Motley Fool 14 days ago

NVO

LLY

VKTX
Where Will Viking Therapeutics Be in 3 Years?

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Motley Fool 14 days ago

VKTX
1 Beaten-Down Stock to Buy and Hold for 10 Years

Viking Therapeutics (NASDAQ: VKTX) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. Should you steer clear of Viking Therapeutics? The biotech industry can be volatile, especially for small- or mid-cap drugmakers that don't have a single product on the market, a description that fits Viking Therapeutics.

Motley Fool 15 days ago

VKTX
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker. The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies.

Motley Fool 16 days ago

PFE

VKTX
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain

Both Pfizer and Viking aim to enter the high-growth weight loss drug market. Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Today, Eli Lilly and Novo Nordisk dominate with their well-known treatments: Lilly makes tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss.

Motley Fool 16 days ago

PFE

VKTX
Why Viking Therapeutics Stock Popped Again Today

Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.

Motley Fool 16 days ago

VKTX
Why Viking Therapeutics Stock Popped Today

2025 is the year we learn whether Viking Therapeutics stock will be a winner.

Motley Fool 17 days ago

VKTX

TFC
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025

Viking Therapeutics (NasdaqCM:VKTX) reported a quarterly net loss of $45.63 million for Q1 2025, up from $27.36 million in the previous year, pushing the stock up 7.7% over the last week. Despite the larger loss, broader market trends indicate that investors focused on overall market optimism, especially in technology and biotech sectors, may have driven this move. Market indices were buoyant, with the Nasdaq Composite up 2.3% amid positive earnings reports and expectations of tariff policy...

Simply Wall St. 21 days ago

VKTX
Q1 2025 Viking Therapeutics Inc Earnings Call

Q1 2025 Viking Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 21 days ago

VKTX
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips

VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.

Zacks 22 days ago

VKTX
Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ...

Viking Therapeutics Inc (VKTX) reports significant progress in clinical trials and maintains a strong cash position despite increased R&D and administrative costs.

GuruFocus.com 22 days ago

VKTX
Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]

Insider Monkey 22 days ago

VKTX
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks 23 days ago

VKTX
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.

Zacks 24 days ago

LLY

VKTX

NVO

Performance Overview

Return	1VT.F	S&P 500 (^GSPC)
YTD	-38.21%	+0.60%
1-Year	-62.58%	+11.70%
3-Year	+943.73%	+47.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viking Therapeutics, Inc. (1VT.F)

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

3 Monster Stocks in the Making

Why Viking Therapeutics Stock Surged Nearly 20% Higher in April

Why Viking Therapeutics Stock Was Victorious This Week

Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

Is Novo Nordisk Stock a Buy?

Where Will Viking Therapeutics Be in 3 Years?

1 Beaten-Down Stock to Buy and Hold for 10 Years

Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain

Why Viking Therapeutics Stock Popped Again Today

Why Viking Therapeutics Stock Popped Today

Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025

Q1 2025 Viking Therapeutics Inc Earnings Call

Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips

Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ...

Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Performance Overview